|
|
|
|
|
Last Trade
|
Last Trade:
$5.53
|
Change:
-0.07 (-1.25%)
|
Trade Time:
Dec 13
|
Market Cap:
$126.04M
|
|
|
|
|
|
|
Description of Business
|
|
We are a clinical-stage company focused on developing innovative gene therapies
for neurological diseases. We are developing a pipeline of innovative product
candidates for the treatment of these debilitating diseases, including
Parkinson's disease, GM1 gangliosidosis, and GM2 gangliosidosis (including
Tay-Sachs disease and Sandhoff disease). We are dedicated to realizing the
potential of gene therapies to offer transformative patient outcomes in areas of
high unmet medical need. We have assembled a portfolio of gene therapies in
partnership with leading scientific institutions and have built a team with
extensive experience in the gene therapy space. We will continue to build
integrated internal development capabilities from product development through
commercialization, with a focus on accelerating the pace of product development
in the clinic.
|
|
|
|